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No antimicrobial resistance research agenda without 
tuberculosis
The global fight against antimicrobial resistance (AMR) 
needs a unified, multidisciplinary, and intersectoral 
approach by a community of stakeholders and 
implementers working towards common goals. As 
such, the impetus created by the WHO priority list of 
antibiotic-resistant bacteria1 and increasing focus from 
the international public health community are timely. 
However, tuberculosis is not sufficiently emphasised 
in the AMR discussion at the highest decision-making 
level. Tuberculosis is the top infectious disease killer 
globally,2 and is responsible for around a quarter of 
all deaths caused by AMR bacteria,3 with nearly half a 
million estimated multidrug-resistant tuberculosis cases 
annually.2 This insufficiency of emphasis is despite the 
global public health threat2 that multidrug-resistant 
tuberculosis poses, and the potential for knowledge 
sharing given the experience accumulated over decades.
For example, although specific large grants for 
tuberculosis drug development are available from the 
European Commission, many UK funders do not include 
tuberculosis in AMR grants: omissions include a 2018 
£32 million call for AMR capital funding.4 In the USA, for 
2018 AMR category projects from the National Institutes 
of Health, only around 10% of grants and funding for 
research explicitly mentioned tuberculosis in the title. 
At the global level, major initiatives driving research 
and development into new antimicrobials also seem to 
exclude tuberculosis. Both the 2017–18 and 2018–19 
annual reports from the Combating Antibiotic Resistant 
Bacteria initiative did not mention tuberculosis. 
The Global Antibiotic Research and Development 
Partnership’s four programmes do not include a focused 
multidrug-resistant tuberculosis channel. Another new 
initiative by the Bill & Melinda Gates Medical Research 
Institute has tuberculosis as one of the three diseases in 
focus, but the translational research is not specifically 
targeted at drug resistance. Finally, the lack of research 
and development investment is reflected in reviews5 on 
the progress in antimicrobial resistance that completely 
ignore tuberculosis. Ultimately, the TB Alliance, which 
antedates more recent AMR awareness, is the sole 
global initiative dedicated entirely to tuberculosis drug 
development.
The reasons for this lack of attention originate from well 
known difficulties in advocating for tuberculosis action 
in general,6 but it could also be because of misconcep-
tions. First, the natural history of tuberculosis suggests 
that it requires complex interventions through new 
combination regimens rather than a single new agent. 
However, tuberculosis has the same needs as many other 
bacterial diseases: shorter treatment regimens alongside 
rapid diagnostics. Second, the argument that tuberculosis 
is already supported by dedicated long-term programmes 
for research and development is invalid: far less than the 
50% of the estimated need is being mobilised.7
To address the huge problem of multidrug-resistant 
tuberculosis, Mycobacterium tuberculosis must syste-
matically be included as an integral part of all AMR 
priority lists for research and development financing. 
For example, perhaps because tuberculosis is only a 
footnote on the key WHO priority list table, despite 
having a chapter in the final report, a 2019 systematic 
review8 of AMR modelling has a blank next to the WHO 
categorisation of priority level for M tuberculosis. The 
inclusion of tuberculosis would be consistent with 
previous lists of top AMR pathogens, beyond the final 
WHO list, such as those from the US Centers for Disease 
Control and Prevention and Longitude Prize Team.
By assuming tuberculosis programmes are inherently 
separate from research initiatives for other bacteria, 
both tuberculosis and other pathogens will suffer a 
lack of shared infrastructure, knowledge, investment, 
and research overlap.9 For example, new funding 
frameworks could be introduced to expand further and 
jointly develop new antimicrobials and therapies for 
all bacteria, including and emphasising tuberculosis. 
The attempt by the Innovative Medicines Initiative to 
develop an integrated research platform within which 
tuberculosis is a pillar is an important step forward.10 
The global laboratory initiative, long-established 
surveillance networks, and WHO reports are all aspects of 
the tuberculosis world, within which multidrug-resistant 
tuberculosis focus is increasing, which could provide 
important lessons for the wider AMR field.3
Despite a small increase in new drug financing, in 
2017–18,7 tuberculosis has faced a long-term lack 
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of focus on investments in drug development when 
compared with infectious diseases with similar human 
burden such as HIV and malaria.7 In the AMR arena, 
it seems that tuberculosis is also not prioritised, 
perhaps because it does not cause a problem in high-
income settings, where concern about AMR is driven 
by hospital-associated infections. With the new global 
focus on AMR, the knowledge of, and lessons learned 
from, tuberculosis programmes and research, should be 
embraced within a unified platform across all income 
groups to move forward more quickly and reduce the 
burden of all infections caused by AMR pathogens.
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